SLS SELLAS Life Sciences Group Inc

$SLS Going to be revolutionary beyond anything imaginable. After 15 years, SLS will suddenly become the most recognized bio tech name overnight. Then we’ll all understand why no BP buyout over $10.9B has happened in 2026. CELGENE $74B deal adjusted for inflation kind of future value on deck for SLS…$96B after all indications and combos are approved! Not sure what initial buyout will be but know it will be much more than the $2.3B MC now. I am no biostatistician or Scientologist or chartist, just a retired businessman. I am betting patients and doctors will want the quality of life and promise of life these drugs can bring. A forward thinking BP wanting to be number one top of mind brand and number one in sales and profit will quickly grow this platform bigger than Keytruda, yet Keytruda WILL NOT have to disappear. Rather, some already highly successful drugs will become even more successful because of GPS and SLS009 and GPS+. My two cents worth.😎❤️🙏

$SLS it's just fake money untl the data guys, don't get sad. I lose or gain a quarter mil a day. It means nothing.

$SLS I have a strong conviction that REGAL’s final HR will be something extraordinary. The survival signals, the historical BAT data and the journey this trial has taken reinforce that conviction. $SLS is on the verge of a defining moment.

$SLS IF SLS used the embargo process as I believe to legally hold results then Nov 4 at 9am is the key date. Unfortunately, despite many attempts to verify with ASH in Washington DC that SLS did/did not submit an abstract early (repeatedly told this information is under embargo) then we are either following exactly what happened with RVMD last year, a huge move up after the abstract goes online followed with details and a presentation live at the conference OR a buyer imo must step up on merger Monday October 26 or November 2 before the online posting. The Majors however have been proven to be cheap/frugal and arrogant. Therefore, I expect the results Nov 4 at 9am. GLTA

$SLS Weekend starting here in Europe. Who wants to raise a beer with me to the birthday of this wonderful company? Happy 15th ! 🎉

$SLS Finding 40-45 AML CR2 patients without a transplant who have already survived for over 30/40/50 months is something you simply won't find anywhere else in the world today. Go ahead and try to search for it. That alone is why the REGAL study is going to be an absolute sensation! Super-

$SLS 55.1M shares short. 27.7% of the float. 9.45 days to cover. Now imagine what happens when the REGAL blind comes off. What if strategic discussions with Big Pharma are already underway, with a deal waiting for clinical confirmation? GPS targets WT1 across multiple cancers. SLS009 is opening new oncology opportunities, including a compelling preclinical pancreatic cancer signal: 36.5% apoptosis in a resistant tumor model versus 2.8% with daraxonrasib alone. SELLAS had $138.3M in cash at June 30, 2026. A successful REGAL readout combined with a strategic deal could transform the company’s valuation overnight. And with this level of short interest, the market reaction could be explosive. Sometimes the biggest upside comes when several catalysts converge at once.

$SLS happy birthday to you Happey birthday to you Happy birthday to sellas Happy birthday to 40 Billy

$SLS Up down, down up… how long has this accumulation zone been going on? I expect to see a lot of 13F’s in the coming weeks.

$SLS I know everyone’s frustrated that the 79th and 80th patient hasn’t died yet. Which is kind of fucked up. That’s really good news for us and the patients. The 10% up and downs just roll with it.

$SLS $SLS — Happy 15th Birthday, SELLAS! 🎂🎉 Best wishes to the team. Above all, we wish true healing and recovery to the patients and their families. And for us, the resilient investors who stayed the course: may this milestone pave the way to heal our portfolios and hit that $40B valuation. 🚀🔥

$SLS I am expecting much better results from GPS compared with Moderna’s vaccine. On evaluation comparison: market cap for Moderna is inflated, for SLS just the opposite! 

$SLS Monday through Wednesday, we pushed higher as reported borrow availability surged to 1.4 million shares. Now it has collapsed to just 45,000. That is a dramatic shift in a very short time, right as the stock tries to build momentum toward a larger breakout. Borrow availability alone doesn’t prove who is borrowing or why, but the shrinking supply is impossible to ignore. When momentum is building, a thin pool of available shares can make every move matter more. ASH late-breaking abstract submissions close October 28. With REGAL’s 80th event still a major catalyst ahead, $SLS is entering a pivotal stretch with multiple potential drivers. Pressure is building. The next move could be powerful.

$SLS Happy Anniversary! We will not be able to celebrate another one under the name of Sellas, but your legacy will shine for a long long time ! 🎉🦖🦖🦖🦖#40billy

$SLS Sellas, today is your birthday—and as is customary for any proper birthday, a toast is in order. Surely you wouldn’t want to come across as stingy, would you? So, today we’re expecting—at the very least—a substantial toast to accompany a lavish, feast-like lunch. We’ll be waiting patiently!

$SLS payday! Added another 116 shares (2,446 total!) . This might be the last payday before something big 🤞🥳 fingers crossed!

$SLS GOOD morning my friends SLS showing strength is a very red market is very bullish. my friends SLS one of my major picks going into 2026 and 2027 for major moves higher with huge upside and possible a BO candidate down the road. my friend with uncertain times in the markets all health and BIO stocks may benefit with increase money flow into their companies. have a blessed day plus a safe weekend

$SLS good morning, fellow bulls ☀️ I hear it’s a special someone’s birthday today. 🎂 #40billy #godzilla

$SLS This flatline implies the hazard ratio has collapsed toward zero, signaling that the active GPS arm has hit the holy grail of oncology: the "tail of the curve." When the ledger finally settles, the delta between the two arms will be wider than anyone modeled. Big Pharma will be looking at a biological monopoly that has permanently rewritten human survival baselines. If you’re serious about your capital, at least learn how event-driven statistical math works. The trial doesn't unblind on a random Tuesday just because you have options expiring.

$SLS push to $12 into the close in anticipation of another week/weekend passing with no 80th.